

# Beneficial Effects of Finerenone: FINE-HEART

- Among patients with CKM syndrome, all-cause death was reduced with finerenone with nominal significance.
- This mortality signal was further substantiated by clinically relevant benefits observed across a broad range of other cardiovascular-kidney outcomes, including kidney disease progression, HF hospitalizations, all-cause hospitalizations, new-onset atrial fibrillation and major adverse cardiovascular events.
- Treatment effects were consistent across all tested clinical subgroups, including those with multiple, intersecting CKM condition.

## FINE-HEART

Cumulative incidence of key efficacy outcomes. Incidence of cardiovascular (CV) death (primary outcome) **(a)**; HF hospitalization **(b)**; kidney composite outcome (sustained decrease in eGFR to  $\geq 50\%$  from baseline, sustained decline in eGFR to  $< 15 \text{ ml min}^{-1} 1.73 \text{ m}^{-2}$ , kidney failure and death due to kidney failure) **(c)**; and all-cause death **(d)**.

